gossypol has been researched along with Cancer of Head in 8 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Given the evidence of activity in xenograft models, treatment with AT-101 in combination with docetaxel is a therapeutic doublet of interest in metastatic head and neck squamous cell carcinoma." | 2.82 | A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. ( Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP, 2016) |
| " For the pharmacokinetic analysis, plasma AT-101 levels were measured by HPLC in blood samples collected from patients enrolled in our clinical phase I/II study." | 2.80 | Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. ( Dubbelman, R; Hoebers, FJ; Kuipers, GK; Lafleur, MV; Slotman, BJ; Stoter, TR; van den Brekel, MW; Verheij, M; Zerp, SF, 2015) |
| " Thus, we hypothesized that BH3-mimetic drugs that antagonize Bcl-2 family proteins may exert a greater efficacy when dosed metronomically." | 1.38 | Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. ( Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Melo, G | 1 |
| Silva, CAB | 1 |
| Hague, A | 1 |
| Parkinson, EK | 1 |
| Rivero, ERC | 1 |
| Lin, YL | 1 |
| Yuksel Durmaz, Y | 1 |
| Nör, JE | 3 |
| ElSayed, ME | 1 |
| Zerp, SF | 1 |
| Stoter, TR | 1 |
| Hoebers, FJ | 1 |
| van den Brekel, MW | 1 |
| Dubbelman, R | 1 |
| Kuipers, GK | 1 |
| Lafleur, MV | 1 |
| Slotman, BJ | 1 |
| Verheij, M | 1 |
| Swiecicki, PL | 1 |
| Bellile, E | 1 |
| Sacco, AG | 1 |
| Pearson, AT | 1 |
| Taylor, JM | 1 |
| Jackson, TL | 1 |
| Chepeha, DB | 1 |
| Spector, ME | 1 |
| Shuman, A | 1 |
| Malloy, K | 1 |
| Moyer, J | 1 |
| McKean, E | 1 |
| McLean, S | 1 |
| Sukari, A | 1 |
| Wolf, GT | 1 |
| Eisbruch, A | 1 |
| Prince, M | 1 |
| Bradford, C | 1 |
| Carey, TE | 3 |
| Wang, S | 4 |
| Worden, FP | 1 |
| Benvenuto, M | 1 |
| Mattera, R | 1 |
| Masuelli, L | 1 |
| Taffera, G | 1 |
| Andracchio, O | 1 |
| Tresoldi, I | 1 |
| Lido, P | 1 |
| Giganti, MG | 1 |
| Godos, J | 1 |
| Modesti, A | 1 |
| Bei, R | 1 |
| Imai, A | 1 |
| Zeitlin, BD | 1 |
| Visioli, F | 1 |
| Dong, Z | 1 |
| Zhang, Z | 1 |
| Krishnamurthy, S | 1 |
| Light, E | 1 |
| Worden, F | 1 |
| Oliver, CL | 1 |
| Bauer, JA | 2 |
| Wolter, KG | 1 |
| Ubell, ML | 1 |
| Narayan, A | 1 |
| O'Connell, KM | 1 |
| Fisher, SG | 1 |
| Wu, X | 1 |
| Ji, M | 1 |
| Bradford, CR | 2 |
| Trask, DK | 1 |
| Kumar, B | 1 |
| Los, G | 1 |
| Castro, J | 1 |
| Lee, JS | 1 |
| Chen, J | 1 |
1 review available for gossypol and Cancer of Head
| Article | Year |
|---|---|
Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gossypol; Head and Neck Neoplasms; Humans; Proto | 2022 |
2 trials available for gossypol and Cancer of Head
| Article | Year |
|---|---|
Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line | 2015 |
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2016 |
5 other studies available for gossypol and Cancer of Head
| Article | Year |
|---|---|
Synergistic combination of small molecule inhibitor and RNA interference against antiapoptotic Bcl-2 protein in head and neck cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Gossypol; Head and Neck Neoplasms; Humans; Proto-Oncogen | 2013 |
(±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Reg | 2017 |
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2012 |
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Topics: Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolif | 2004 |
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Go | 2005 |